According to the latest research by Future Market Insights, chemotherapy-induced oral mucositis market is set to experience positive growth during the year 2021-2031. The global oral mucositis market is witnessing demand every year as cases of oral mucositis become apparent each year.
This demand fluctuates from year to year based on a variety of conditions. This market covers the prescription and sales of oral mucositis drugs worldwide. Oral mucositis is swelling of the tissues of the oral cavity. This medical condition occurs as a common side effect of radiation or chemotherapy.
Oral mucositis is a common health problem caused by cancer treatment and other factors, so this market faces demand in many parts of the world. Therefore, the customer base of oral mucositis in the global market is diversified. Increase in usage of chemotherapeutic agents due to increasing incidence of cancers is the major growth driver of chemotherapy-induced oral mucositis treatment market.
To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-13706
What is Driving Demand for Chemotherapy-Induced Oral Mucositis Market?
There are many growing drivers of the oral mucositis market that frequently affect the market. One of the major driver in the oral mucositis market is the increased detection of cancer. This is also the case for the discovery of cases of head and neck cancer. In recent years, the number of patients with cancer has increased.
This also creates a window for oral mucositis and industrial demand window for oral mucositis. Another important factor in the oral mucositis market is the increased elderly population. People get older and more susceptible to cancer because of their current lifestyle.
These factors also affect the oral mucositis market as the increase in the number of patients receiving chemotherapy each year. Increasing prevalence of cancer propel the growth of Chemotherapy-Induced Oral Mucositis Market.
Increasing Incidence of Oral Mucositis Likely to Augment Chemotherapy-Induced Oral Mucositis Sales
Chemotherapy treatment causes oral mucositis in 35% of patients. The incidence of oral mucositis was particularly high in patients with tumours in the oropharynx or nasopharynx, patients receiving concomitant chemotherapy, patients with total doses greater than 5000 cGy, and patients. Treated with an altered split radiation schedule.
Enzychem Lifesciences, has a mid-term experimental oral compound called EC18 for OM induced by chemoradiation therapy.
U.S. And Canada Chemotherapy-Induced Oral Mucositis Market Outlook
About half a million people in the United States suffer from oral mucositis each year, and oral mucositis represents a new market in which unmet health care needs are largely intrinsically a long-standing problem. It is estimated that 40% of cancer patients who receive standard chemotherapy will develop oral mucositis.
The Centres for Disease Control and Prevention estimates that approximately 650,000 cancer patients in the United States receive chemotherapy in an outpatient environment each year.Generally speaking, there is an agreement that there are about 500,000 oral mucositis cases each year in the United States today. Adding financial burden makes the market opportunity to solve oral mucositis clearer.
Innovation Pharma evaluated Buriracizine in a fast-track designation in a gargle, Phase II clinical trial to reduce oral mucositis in patients with head and neck cancer (HNC) who received chemo radiation therapy. NCI scientists developed palifermin, a very successful treatment for preventing and treating oral mucositis.
Europe Demand Outlook For C Hemotherapy-Induced Oral Mucositis
Mucositis is a common complication of chemotherapy, radiation therapy, and targeted formulations. This often affects chemotherapy compliance because it induces schedule delays, treatment interruptions or discontinuations. Also, the economic impact associated with the management of mucositis is local, and some estimates of additional hospital costs due to these clinical conditions have recently been reported.
The ability to determine risk factors for mucositis, detect early onset, accurately assess the degree of toxicity, and plan multidisciplinary management ensures quality of life for all patients and of this drug it is an important factor in avoiding unnecessary capacity reduction or discontinuation in the treatment.
BMG Pharma in 2018 got the European regulatory approval for its GelX product to be used for the prevention of oral mucositis. episil® (Camurus AB) oral liquid – a treatment for intraoral pain caused by oral mucositis
Who Are The Key Manufacturers And Suppliers of Chemotherapy-Induced Oral Mucositis Market?
Some of the key players operating in the Chemotherapy-Induced Oral Mucositis Market are
- Izun Pharmaceuticals
- Soleva Pharma
- Aurora Bioscience
- INNOVATION Pharma
- Camurus AB
- Monopar Therapeutics
- Prothex Inc.
- Access Pharmaceutical Inc.
- Swedish Orphan Biovitrum AB
- NeoMedLight
MuGard®, Soleva Pharma Oral mucoadhesive is indicated for the management of oral mucositis/stomatitis and all kinds of oral wounds (inflammation and damage) including inflammation/ulcer pain and traumatic ulcers. As a result of intraoral surgery or improper fit of dentures or braces.
For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-13706
Why Future Market Insights?
- Comprehensive analysis on evolving purchase pattern across different geographies
- Detailed insights of market segments and sub-segments for historical as well as forecast period
- A competitive analysis of prominent players and emerging players in the keyword market
- Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years
Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario
About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact Us:
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com